This clinical trial focuses on individuals with Hemophilia A, a genetic disorder that affects the blood’s ability to clot properly, leading to excessive bleeding. The study involves a treatment called BMN 270, also known as valoctocogene roxaparvovec, which is a gene therapy designed to help the body produce more of a protein called Factor VIII, essential for blood clotting. This treatment is administered as a solution for infusion, meaning it is given directly into the bloodstream through a vein.

The purpose of this study is to evaluate the long-term safety of BMN 270 in participants who have previously received this treatment in earlier clinical trials. Participants will be monitored over an extended period to observe any potential side effects or health changes. The study will look for specific events such as liver problems, blood clots, the development of inhibitors to Factor VIII, and any transmission of the treatment to others. Additionally, the study will assess changes in bleeding rates, Factor VIII activity levels, and the use of other medications for managing Hemophilia A.

Participants will also provide feedback on their overall health and quality of life throughout the study. This feedback will help researchers understand the impact of BMN 270 on daily living and any changes in the severity of symptoms. The study aims to gather comprehensive data to ensure the treatment’s safety and effectiveness for individuals with Hemophilia A over the long term.